HRP20211978T1 - Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe - Google Patents
Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe Download PDFInfo
- Publication number
- HRP20211978T1 HRP20211978T1 HRP20211978TT HRP20211978T HRP20211978T1 HR P20211978 T1 HRP20211978 T1 HR P20211978T1 HR P20211978T T HRP20211978T T HR P20211978TT HR P20211978 T HRP20211978 T HR P20211978T HR P20211978 T1 HRP20211978 T1 HR P20211978T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims 49
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title claims 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title claims 3
- 230000008685 targeting Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 65
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 210000004027 cell Anatomy 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 230000003834 intracellular effect Effects 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 230000000139 costimulatory effect Effects 0.000 claims 5
- 230000009826 neoplastic cell growth Effects 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims 3
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 101150030213 Lag3 gene Proteins 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 229910021478 group 5 element Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims 1
- 102100036008 CD48 antigen Human genes 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- -1 CD86 Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims 1
- 108090000177 Interleukin-11 Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 claims 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000000899 immune system response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Claims (33)
1. Kimerični antigenski receptor (CAR), koji sadrži izvanstaničnu domenu vezanja antigena na G-proteinom spojen receptor obitelji C skupine 5 element D (GPRC5D), domena transmembrane i unutarstaničnu domena, pri čemu izvanstanična domena vezanja antigena sadrži:
(a) varijabilnu regiju teškog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:208, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:209, i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:210; i varijabilnu regiju lakog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:211, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:212 i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:213;
(b) varijabilnu regiju teškog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:214, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:215, i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:216; i varijabilnu regiju lakog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:217, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:218 i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:219;
(c) varijabilnu regiju teškog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:220, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:221, i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:222; i varijabilnu regiju lakog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:223, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:224 i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:225; ili
(d) varijabilnu regiju teškog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:226, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:227, i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:228; i varijabilnu regiju lakog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:229, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:230 i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:231.
2. Kimerični antigenski receptor (CAR) sukladno patentnom zahtjevu 1, pri čemu se izvanstanična domena vezivanja antigena kimeričnog antigenskog receptora (CAR) veže na GPRC5D s afinitetom vezivanja (Kd) od oko 1 × 10-9 M do oko 3 × 10-6 M.
3. Kimerični antigenski receptor (CAR) sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, pri čemu je ta izvanstanična domena vezivanja antigena promjenjivi fragment jednog lanca (scFv), Fab koji je izborno unakrsno povezan, ili F(ab)2, izborno jedan ili više od tih scFv, Fab i F(ab)2 su obuhvaćeni u proiteinu fuzije s heterolognom sekvencom da bi se formirala izvanstanična domena vezivanja antigena.
4. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-3, pri čemu ta izvanstanična domena vezivanja antigena sadrži veznik između promjenjive regije teškog lanca i promjenjive regije lakog lanca.
5. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-4, pri čemu:
(a) varijabilna regija teškog lanca koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:57, i varijabilna regija lakog lanca koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:58;
(b) varijabilna regija teškog lanca koja sadrži sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:61, i varijabilna regija lakog lanca koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:62;
(c) varijabilna regija teškog lanca koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:65, i varijabilna regija lakog lanca koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:66; ili
(d) varijabilna regija teškog lanca koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:69, i varijabilna regija lakog lanca koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:70.
6. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-5, pri čemu je izvanstanična domena vezivanja antigena scFv koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:114, SEK ID BR:115, SEK ID BR:116, ili SEK ID BR:117.
7. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-6, pri čemu varijabilna regija teškog lanca sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:57, i varijabilna regiju lakog lanca koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:58.
8. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-6, pri čemu varijabilna regija teškog lanca koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:61, i varijabilnu regija lakog lanca koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:62.
9. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva (1-6), pri čemu varijabilna regija teškog lanca sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:65; i varijabilnu regiju lakog lanca koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:66.
10. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-6, pri čemu varijabilna regija teškog lanca sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:69, i varijabilnu regiju lakog lanca koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:70.
11. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-7, pri čemu varijabilna regiju teškog lanca koja sadrži CDR1 koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:208, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:209, i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:210; i ta varijabilna regija lakog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:211, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:212 i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:213.
12. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-6 i 8, pri čemu ta varijabilna regija teškog lanca sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:214, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:215, i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:216; i varijabilnu regiju lakog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:217, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:218 i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:219.
13. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-6 i 9, pri čemu ta varijabilna regija teškog lanca sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:220, CDR2 koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:221, i CDR3 koja sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:222; i varijabilnu regiju lakog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:223, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:224 i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:225.
14. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-6 i 10, pri čemu varijabilna regija teškog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:226, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:227, i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:228; i varijabilnu regiju lakog lanca koja sadrži CDR1 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:229, CDR2 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:230 i CDR3 koji sadrži aminokiselinsku sekvencu navedenu u SEK ID BR:231.
15. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-14, pri čemu (a) domena transmembrane sadrži CD8 polipeptid, CD28 polipeptid, CD3zeta polipeptid, CD4 polipeptid, 4-1BB polipeptid, OX40 polipeptid, ICOS polipeptid, CTLA-4 polipeptid, PD-1 polipeptid, LAG-3 polipeptid, 2B4 polipeptid, BTLA polipeptid, sintetički peptid (nije zasnovan na proteinu povezanim s odgovorom imunosnog sustava), ili njihovoj kombinaciji, izborno pri čemu domena tansmembrane sadrži CD8 polipeptid ili CD28 polipeptid; i/ili (b) unutarstanična domena sadrži CD3zeta polipeptid.
16. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-15, pri čemu unutarstanična domena nadalje sadrži najmanje jednu signalnu regiju, izborno pri čemu najmanje jedna signalna regija sadrži CD28 polipeptid, 4-1BB polipeptid, OX40 polipeptid, ICOS polipeptid, DAP-10 polipeptid, PD-1 polipeptid, CTLA-4 polipeptid, LAG-3 polipeptid, 2B4 polipeptid, BTLA polipeptid, sintetički peptid (nije zasnovan na proteinu povezanim sa odgovorom imunosnog sustava), ili nekoj kombnaciji navedenih.
17. Kimerični antigenski receptor (CAR) sukladno patentnom zahtjevu 15 ili patentnom zahtjevu 16, pri čemu najmanje jedna signalna regija je kostimulacijska signalna regija, izborno pri čemu kostimulacijska signalna regija sadrži signalnu regiju CD28 polipeptida, 4-1BB polipeptida, OX40 polipeptida, ICOS polipeptida, DAP-10 polipeptida, ili neku njihovu kombinaciju.
18. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-17, pri čemu:
(a) domena transmembrane sadrži CD28 polipeptid, i unutarstaničnu domenu sadrži CD3zeta polipeptid i signalna domena sadrži CD28 polipeptid; ili
(b) domena transmembrane sadrži CD8 polipeptid, i unutarstanična domena sadrži CD3zeta polipeptid i signalna domena sadrži 4-1BB polipeptid.
19. Kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-17, pri čemu ta domena transmembrane sadrži CD28 polipeptid, i unutarstanična domena sadrži CD3zeta polipeptid i signalna domena sadrži 4-1BB polipeptid.
20. Imunoreaktivna stanica koja sadrži kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjeva 1-19.
21. Imunoreaktivna stanica sukladno patentnom zahtjevu 20, pri čemu je ta imunoreaktivna stanica transducirana s kimeričnim antigenskim receptorom (CAR), i izborno ta stanica je dodatno transducirana s (a) najmanje jednim kostimulacijskim ligandom kao što je imunoreaktivna stanica koja eksprimira najmanje jedan kostimulacijski ligand; i/ili (b) najmanje jedan citokin takav da imunoreaktivna stanica izlučuje najmanje jedan citokin; i/ili pri čemu taj kimerični antigenski receptor (CAR) je konstitutivno eksprimiran na površini imunoresponsivne stanice; i/ili pri čemu je najmanje jedan kostimulacijski ligand odabran iz skupine koja sadrži 4-1BBL, CD80, CD86, CD70, OX40L, CD48, TNFRSF14, i njihove kombinacije; i/ili najmanje jedan citokin je odabrana iz skupine koja sadrži IL-2, IL-3, IL-6, IL-7, IL-11, IL-12, IL-15, IL-17, IL-21, i njihove kombinacije.
22. Imunoreaktivna stanica sukladno patentnom zahtjevu 20 ili patentnom zahtjevu 21, pri čemu je ta imunoreaktivna stanica odabrana iz skupine koja sadrži T stanicu, stanicu prirodnog ubojicu (NK), matičnu stanicu ljudskog embria, limfoidnu progenitornu stanicu, stanicu prekursora T stanice, i višepotentnu matičnu stanicu iz koje je moguće diferencirati limfoidne stanice.
23. Imunoreaktivna stanica sukladno patentnom zahtjevu 22, pri čemu je ta imunoreaktivna stanica T stanica, izborno pri čemu ta T stanica je citotoksični T limfocit (CTL) ili regulacijska T stanica (Treg).
24. Molekula nukleinske kiseline koji kodira kimerični antigenski receptor (CAR) sukladno bilo kojem od patentnih zahtjevu 1-19, i izborno pri čemu molekula nukleinske kiseline sadrži tu sekvencu nukleotida navedenu u SEK ID BR: 397, SEK ID BR:398, SEK ID BR:399, ili SEK ID BR:400.
25. Vektor koji sadrži molekulu nukleinske kiseline sukladno patentnom zahtjevu 24, i izborno pri čemu je taj vektor gama-retroviralni vektor.
26. Vektor koji sadrži molekulu nukleinske kiseline sukladno patentnom zahtjevu 24, pri čemu je taj vektor lentiviralni vektor.
27. Stanica domaćin koja eksprimira molekulu nukleinske kiseline sukladno patentnom zahtjevu 24, i izborno pri čemu je ta stanica domaćin neka T stanica.
28. Imunoreaktivna stanica sukladno bilo kojem od patentnih zahtjeva 20-23 za uporabu za smanjenje opterećenosti tumorom kod nekog subjekta i/ili za uporabu u povećanju ili produženju opstanka subjekta koji ima neoplaziju.
29. Imunoreaktivna stanica za uporabu sukladno patentnom zahtjevu 28, pri čemu je taj tumor i/ili neoplazija multiple mijelom ili Waldenstrom’s makroglobulinemija, i izborno tumor i/ili neoplazija je multiple mijelom.
30. Imunoreaktivna stanica za uporabu sukladno patentnom zahtjevu 28 ili patentnom zahtjevu 29, pri čemu je taj subjekt čovjek.
31. Neki in vitro ili ex vivo postupak za proizvodnju imunoreaktivne stanice koja se veže na G-proteinom spojen receptor obitelji C skupine 5 element D (GPRC5D), sadrži uvođenje u imunoreaktivnu stanicu molekule nukleinske kiseline sukladno patentnom zahtjevu 24.
32. Farmaceutski pripravak koji sadrži učinkovitu količinu imunoreaktivne stanice sukladno bilo kojem od patentnih zahtjeva 20-23 i farmaceutski prihvatljiv ekscipijens, i izborno taj farmaceutski pripravak je za liječenje neoplazije.
33. Pribor za liječenje višestrukog mijeloma, koji sadrži imunoreaktivnu stanicu sukladno bilo kojem od patentnih zahtjeva 20-23, i izborno taj pribor nadalje sadrži pisana uputstva za uporabu imunoreaktivne stanice za liječenje subjekta koji boluje od neoplazije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088286P | 2014-12-05 | 2014-12-05 | |
| PCT/US2015/064102 WO2016090312A1 (en) | 2014-12-05 | 2015-12-04 | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
| EP15865633.0A EP3227339B1 (en) | 2014-12-05 | 2015-12-04 | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211978T1 true HRP20211978T1 (hr) | 2022-04-01 |
Family
ID=56092565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211978TT HRP20211978T1 (hr) | 2014-12-05 | 2015-12-04 | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10633426B2 (hr) |
| EP (2) | EP4015534A1 (hr) |
| JP (3) | JP6919091B2 (hr) |
| KR (1) | KR102612367B1 (hr) |
| CN (3) | CN113683711A (hr) |
| AU (2) | AU2015357518B2 (hr) |
| BR (1) | BR112017011920A2 (hr) |
| CA (1) | CA2969864A1 (hr) |
| CY (1) | CY1125008T1 (hr) |
| DK (1) | DK3227339T3 (hr) |
| ES (1) | ES2899779T3 (hr) |
| HR (1) | HRP20211978T1 (hr) |
| HU (1) | HUE057777T2 (hr) |
| IL (2) | IL252621B1 (hr) |
| LT (1) | LT3227339T (hr) |
| MX (2) | MX2017007242A (hr) |
| MY (1) | MY192065A (hr) |
| PH (1) | PH12017501044A1 (hr) |
| PL (1) | PL3227339T3 (hr) |
| PT (1) | PT3227339T (hr) |
| RS (1) | RS62870B1 (hr) |
| RU (1) | RU2762359C2 (hr) |
| SA (1) | SA517381665B1 (hr) |
| SG (2) | SG11201704547RA (hr) |
| SI (1) | SI3227339T1 (hr) |
| WO (1) | WO2016090312A1 (hr) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913937QA (en) * | 2014-12-05 | 2020-03-30 | Memorial Sloan Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
| MY192065A (en) | 2014-12-05 | 2022-07-25 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
| FI3298033T4 (fi) | 2015-05-18 | 2023-09-22 | Tcr2 Therapeutics Inc | Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille |
| AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CA3032806C (en) | 2016-08-05 | 2021-04-27 | Y-Biologics Inc. | Antibody to programmed death-ligand 1 (pd-l1) and use thereof |
| AU2017341048A1 (en) | 2016-10-07 | 2019-05-23 | TCR2 Therapeutics Inc. | Compositions and methods for T-cell receptors reprogramming using fusion proteins |
| US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| WO2018127919A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A SIRP1 alpha-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF |
| WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| RU2769513C2 (ru) | 2017-01-05 | 2022-04-01 | Кахр Медикал Лтд. | Слитый белок pd1-4-1bbl и способы его применения |
| AU2018218753A1 (en) * | 2017-02-07 | 2019-09-26 | Daiichi Sankyo Company, Limited | Anti-GPRC5D antibody and molecule containing same |
| SG11201909541WA (en) | 2017-04-26 | 2019-11-28 | Eureka Therapeutics Inc | Chimeric antibody/t-cell receptor constructs and uses thereof |
| US20200239910A1 (en) | 2017-08-09 | 2020-07-30 | Juno Therapeutics, Inc. | Methods and compositions for preparing genetically engineered cells |
| AU2018313950A1 (en) | 2017-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Methods for producing genetically engineered cell compositions and related compositions |
| MA50079A (fr) | 2017-09-07 | 2020-07-15 | Juno Therapeutics Inc | Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire |
| JP7357626B2 (ja) | 2017-11-01 | 2023-10-06 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞の治療用組成物を生成するためのプロセス |
| US20210132042A1 (en) | 2017-11-01 | 2021-05-06 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| US11623961B2 (en) | 2017-11-01 | 2023-04-11 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for B-cell maturation antigen |
| CA3080509A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| EP3710020A4 (en) * | 2017-11-14 | 2021-06-23 | Memorial Sloan-Kettering Cancer Center | IL-36 SECRECTING IMMUNOREACTIVE CELLS AND RELATED USES |
| CN111989106A (zh) | 2017-12-01 | 2020-11-24 | 朱诺治疗学股份有限公司 | 基因工程化细胞的给药和调节方法 |
| CA3084445A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
| KR20200109308A (ko) | 2017-12-08 | 2020-09-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 요법을 위한 표현형 마커 및 관련 방법 |
| AU2018379091A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| MX2020010227A (es) | 2018-03-30 | 2021-02-17 | Eureka Therapeutics Inc | Construcciones dirigidas a cd22 y usos de las mismas. |
| EP3793599A1 (en) * | 2018-05-16 | 2021-03-24 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| MX2021001519A (es) | 2018-08-09 | 2021-05-27 | Juno Therapeutics Inc | Metodos para valorar acidos nucleicos integrados. |
| JP2021533746A (ja) | 2018-08-09 | 2021-12-09 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞およびその組成物を生成するための方法 |
| CN113454115A (zh) * | 2018-10-19 | 2021-09-28 | 纪念斯隆-凯特琳癌症中心 | 靶向唾液酸化路易斯a的嵌合抗原受体及其用途 |
| SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| US20210393689A1 (en) * | 2018-11-01 | 2021-12-23 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| JP2022513685A (ja) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法を用いた処置のための方法 |
| CN113597433A (zh) * | 2019-01-18 | 2021-11-02 | 詹森生物科技公司 | Gprc5d嵌合抗原受体以及表达这些受体的细胞 |
| CN114025788A (zh) | 2019-05-01 | 2022-02-08 | 朱诺治疗学股份有限公司 | 从经修饰的tgfbr2基因座表达重组受体的细胞、相关多核苷酸和方法 |
| WO2020223571A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| MA56206A (fr) | 2019-06-12 | 2022-04-20 | Juno Therapeutics Inc | Combinaison thérapeutique d'une thérapie cytotoxique à médiation cellulaire et d'un inhibiteur d'une protéine de la famille bcl2 pro-survie |
| JP2022545467A (ja) | 2019-08-22 | 2022-10-27 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法 |
| KR20220101641A (ko) | 2019-10-30 | 2022-07-19 | 주노 테라퓨틱스 게엠베하 | 세포 선택 및/또는 자극 장치 및 사용 방법 |
| KR20220146480A (ko) | 2020-01-28 | 2022-11-01 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｔ 세포 형질도입 방법 |
| BR112022020539A2 (pt) | 2020-04-10 | 2023-04-25 | Invivyd Inc | Compostos específicos para proteína s de coronavírus e usos dos mesmos |
| US20230178239A1 (en) | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| KR20230042283A (ko) | 2020-06-26 | 2023-03-28 | 주노 테라퓨틱스 게엠베하 | 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법 |
| CN116802203A (zh) | 2020-11-04 | 2023-09-22 | 朱诺治疗学股份有限公司 | 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| WO2022148370A1 (en) * | 2021-01-05 | 2022-07-14 | Lanova Medicines Development Co., Ltd. | Anti-gprc5d monoclonal antibodies and uses thereof |
| US20240108654A1 (en) | 2021-03-03 | 2024-04-04 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| JP2024511420A (ja) | 2021-03-22 | 2024-03-13 | ジュノー セラピューティクス インコーポレイテッド | ウイルスベクター粒子の効力を評価する方法 |
| EP4314814A1 (en) | 2021-03-22 | 2024-02-07 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
| AU2022253202A1 (en) * | 2021-04-07 | 2023-09-28 | Lg Chem, Ltd. | Gucy2c binding polypeptide and uses thereof |
| EP4334341A2 (en) | 2021-05-06 | 2024-03-13 | Juno Therapeutics GmbH | Methods for stimulating and transducing t cells |
| CN115386010A (zh) * | 2021-05-23 | 2022-11-25 | 上海邦耀生物科技有限公司 | 靶向gprc5d的嵌合抗原受体及其用途 |
| CN116063500A (zh) | 2021-08-30 | 2023-05-05 | 原启生物科技(上海)有限责任公司 | 抗gprc5d抗原结合蛋白及其用途 |
| CA3237175A1 (en) | 2021-11-03 | 2023-05-11 | Janssen Biotech, Inc. | Corticosteriod reduction in treatment with anti-cd38 antibodies |
| WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
| WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023225569A1 (en) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| WO2023240282A1 (en) | 2022-06-10 | 2023-12-14 | Umoja Biopharma, Inc. | Engineered stem cells and uses thereof |
| WO2023250122A1 (en) * | 2022-06-24 | 2023-12-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to enpp1 polypeptides |
| WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| US20240041929A1 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN117229407B (zh) * | 2023-11-14 | 2024-02-20 | 成都优赛诺生物科技有限公司 | 一种靶向gprc5d的单域抗体、嵌合抗原受体及其应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| KR101287395B1 (ko) | 2000-06-16 | 2014-11-04 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 |
| WO2003016553A2 (en) | 2001-08-20 | 2003-02-27 | Genentech, Inc. | Gpcr-like retinoic acid-induced gene 1 protein and nucleic acid |
| US20050019320A1 (en) | 2001-12-27 | 2005-01-27 | Eiji Sugaru | Remedies for anorexia or lifestyle-related diseases and method of screening the same |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20040110139A1 (en) * | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of G protein-coupled receptor 3 expression |
| JP4898120B2 (ja) | 2002-12-20 | 2012-03-14 | アボット バイオセラピューティクス コーポレイション | Ｇｐｒ６４に対する抗体とその利用法 |
| BRPI0407446A (pt) | 2003-02-13 | 2006-01-31 | Pharmacia Corp | Anticorpos para c-met para o tratamento de cânceres |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| MXPA06005941A (es) * | 2003-12-10 | 2006-08-23 | Medarex Inc | Anticuerpos ip-10 y sus usos. |
| US20050266008A1 (en) * | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
| RU2009107277A (ru) | 2006-08-03 | 2010-09-10 | Астразенека Аб (Se) | АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ |
| US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
| EP2141997B1 (en) | 2007-03-30 | 2012-10-31 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| EP2192922A4 (en) | 2007-09-17 | 2010-09-29 | Univ California | INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGING PROSTATE <I> IN SITU CANCER CELLS </ I> |
| US7947807B2 (en) | 2007-10-15 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3) |
| CN101808663B (zh) * | 2007-10-25 | 2015-09-30 | 特雷利斯生物科学股份有限公司 | 抗rsv g蛋白抗体 |
| CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
| EP3450454A1 (en) | 2010-07-22 | 2019-03-06 | John W. Schrader | Cross-protective protection against influenza viral infection |
| EP3305798A1 (en) | 2010-12-09 | 2018-04-11 | The Trustees of The University of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013033626A2 (en) * | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| CN105142677B (zh) * | 2013-02-15 | 2019-08-30 | 加利福尼亚大学董事会 | 嵌合抗原受体及其使用方法 |
| WO2014145252A2 (en) * | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| ES2645393T3 (es) * | 2013-05-29 | 2017-12-05 | Cellectis | Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| EP3164417A1 (en) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| MY192065A (en) | 2014-12-05 | 2022-07-25 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
| SG10201913937QA (en) * | 2014-12-05 | 2020-03-30 | Memorial Sloan Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
| DK3365364T3 (da) | 2015-10-23 | 2024-05-06 | Eureka Therapeutics Inc | Kimære antistof/T-celle-receptorkonstruktioner og anvendelser deraf |
| BR112018011336A2 (pt) | 2015-12-04 | 2018-12-04 | Memorial Sloan-Kettering Cancer Center | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer |
| US20190112380A1 (en) | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| US11768203B2 (en) | 2016-03-31 | 2023-09-26 | University Of Southern California | Highly sensitive and specific luciferase based reporter assay for antigen detection |
| CN108239144B (zh) | 2018-01-26 | 2021-05-25 | 重庆精准生物技术有限公司 | 改造的铰链及其在构建car骨架中的应用 |
| US20210393689A1 (en) | 2018-11-01 | 2021-12-23 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
-
2015
- 2015-12-04 MY MYPI2017000855A patent/MY192065A/en unknown
- 2015-12-04 PT PT158656330T patent/PT3227339T/pt unknown
- 2015-12-04 HR HRP20211978TT patent/HRP20211978T1/hr unknown
- 2015-12-04 HU HUE15865633A patent/HUE057777T2/hu unknown
- 2015-12-04 CN CN202111126092.4A patent/CN113683711A/zh active Pending
- 2015-12-04 AU AU2015357518A patent/AU2015357518B2/en active Active
- 2015-12-04 RU RU2017123551A patent/RU2762359C2/ru active
- 2015-12-04 IL IL252621A patent/IL252621B1/en unknown
- 2015-12-04 EP EP21201788.3A patent/EP4015534A1/en active Pending
- 2015-12-04 LT LTEPPCT/US2015/064102T patent/LT3227339T/lt unknown
- 2015-12-04 DK DK15865633.0T patent/DK3227339T3/da active
- 2015-12-04 CN CN202111119531.9A patent/CN113968912A/zh active Pending
- 2015-12-04 EP EP15865633.0A patent/EP3227339B1/en active Active
- 2015-12-04 IL IL310130A patent/IL310130A/en unknown
- 2015-12-04 JP JP2017529741A patent/JP6919091B2/ja active Active
- 2015-12-04 MX MX2017007242A patent/MX2017007242A/es unknown
- 2015-12-04 KR KR1020177018389A patent/KR102612367B1/ko active IP Right Grant
- 2015-12-04 PL PL15865633T patent/PL3227339T3/pl unknown
- 2015-12-04 BR BR112017011920A patent/BR112017011920A2/pt active Search and Examination
- 2015-12-04 WO PCT/US2015/064102 patent/WO2016090312A1/en active Application Filing
- 2015-12-04 CA CA2969864A patent/CA2969864A1/en active Pending
- 2015-12-04 ES ES15865633T patent/ES2899779T3/es active Active
- 2015-12-04 SI SI201531772T patent/SI3227339T1/sl unknown
- 2015-12-04 SG SG11201704547RA patent/SG11201704547RA/en unknown
- 2015-12-04 RS RS20211596A patent/RS62870B1/sr unknown
- 2015-12-04 CN CN201580075557.4A patent/CN107428829B/zh active Active
- 2015-12-04 SG SG10202007326QA patent/SG10202007326QA/en unknown
-
2017
- 2017-06-05 US US15/613,800 patent/US10633426B2/en active Active
- 2017-06-05 SA SA517381665A patent/SA517381665B1/ar unknown
- 2017-06-05 MX MX2021008798A patent/MX2021008798A/es unknown
- 2017-06-05 PH PH12017501044A patent/PH12017501044A1/en unknown
-
2020
- 2020-02-21 US US16/798,059 patent/US11820806B2/en active Active
- 2020-02-21 US US16/798,151 patent/US10906956B2/en active Active
- 2020-02-21 US US16/798,104 patent/US11866478B2/en active Active
- 2020-11-30 JP JP2020198690A patent/JP2021040652A/ja not_active Withdrawn
-
2022
- 2022-01-06 AU AU2022200052A patent/AU2022200052A1/en active Pending
- 2022-02-07 CY CY20221100105T patent/CY1125008T1/el unknown
-
2023
- 2023-05-12 JP JP2023079310A patent/JP2023091037A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| JP2017537629A5 (hr) | ||
| JP2017537925A5 (hr) | ||
| RU2017123548A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток, и их применение | |
| JP2018504094A5 (hr) | ||
| CN108884164B (zh) | 用于免疫疗法的经修饰细胞 | |
| CN112639102B (zh) | 抗间皮素嵌合抗原受体(car)构建体及其用途 | |
| KR102483822B1 (ko) | 태그된 키메라 이펙터 분자 및 그의 리셉터 | |
| HRP20231542T1 (hr) | Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe | |
| JP2016520074A5 (hr) | ||
| JP2020517295A5 (hr) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| TW201920653A (zh) | 調節細胞表達的生物活性之結合分子 | |
| CN113597433A (zh) | Gprc5d嵌合抗原受体以及表达这些受体的细胞 | |
| IL264144B1 (en) | Antibody 18a2 against claudin and its use | |
| JP2024028944A (ja) | Ｂｃｍａ特異性を有するキメラ抗原受容体およびその使用 | |
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2020509050A5 (hr) | ||
| JP2017513478A5 (hr) | ||
| JP2015527070A5 (hr) | ||
| KR20230137923A (ko) | 신규한 키메라 항원 수용체 및 이의 용도 | |
| KR20230084533A (ko) | 조작된 iPSC 및 보강된 면역 효과기 세포 | |
| KR20230020421A (ko) | Cd70 특이적 융합 단백질을 사용하는 tcr 재프로그래밍을 위한 조성물 및 방법 | |
| CA3208365A1 (en) | Cell therapy compositions and methods for modulating tgf-b signaling | |
| JP6821230B2 (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 |